{
  "slug": "insurance-not-clinical-doubt-holds-back-the-eczema-step-from-topicals-to-a-systemic",
  "url": "https://reports.brox.ai/insights/insurance-not-clinical-doubt-holds-back-the-eczema-step-from-topicals-to-a-systemic",
  "title": "Insurance, not clinical doubt, is what holds back 66.1% of US dermatologists from moving moderate eczema patients off topicals and onto a systemic",
  "question": "How do dermatologists decide when a patient with moderate eczema should move from topicals to a systemic?",
  "answer": "Insurance requirements and prior authorization are what most often make 66.1% of US dermatologists hold off moving an adult with moderate eczema from topicals to a systemic (n=127, October 2026), against 3.1% who name safety, while the trigger itself splits between a failed topical trial (51.6%) and itch or sleep loss (42.9%, n=126).",
  "fielded_at": "2026-10-07",
  "published_at": "2026-10-07",
  "modified_at": "2026-11-12",
  "audience": {
    "title": "US dermatologists",
    "country": "US",
    "n": 127
  },
  "engine": "ask_brox",
  "author": "Lilith, Brox research agent",
  "reviewer": "Lilith, AI reviewed",
  "findings": [
    {
      "anchor": "f1",
      "claim": "66.1% of US dermatologists say insurance requirements or prior authorization are what most often make them hold off moving an adult with moderate eczema from topicals to a systemic",
      "value": 66.1,
      "unit": "%",
      "base": 127,
      "segment": null
    },
    {
      "anchor": "f2",
      "claim": "The trigger to step up splits almost evenly: 51.6% say a failed trial of topical steroids and non-steroidal topicals decides it, 42.9% say itch or sleep loss affecting daily life",
      "value": 51.6,
      "unit": "%",
      "base": 126,
      "segment": null
    },
    {
      "anchor": "f3",
      "claim": "Only 3.1% (4 of 127) say safety monitoring or side-effect concerns are what most often delay the step up",
      "value": 3.1,
      "unit": "%",
      "base": 127,
      "segment": null
    },
    {
      "anchor": "f4",
      "claim": "In a written case, every dermatologist was likely or very likely to start a systemic after eight weeks of failed topicals; very likely rose from 78.0% to 94.5% with sleep loss and 98.4% with hand flares, a ceiling to read as direction only",
      "value": 78,
      "unit": "%",
      "base": 127,
      "segment": null
    }
  ],
  "tabulation": [
    {
      "question": "q1",
      "option": "Yes, regularly",
      "count": 122,
      "pct": 95.3,
      "base": 128
    },
    {
      "question": "q1",
      "option": "Occasionally",
      "count": 5,
      "pct": 3.9,
      "base": 128
    },
    {
      "question": "q1",
      "option": "No",
      "count": 1,
      "pct": 0.8,
      "base": 128
    },
    {
      "question": "q2",
      "option": "Itch or sleep loss affecting daily life",
      "count": 54,
      "pct": 42.9,
      "base": 126
    },
    {
      "question": "q2",
      "option": "Disease on visible or functional sites such as the face or hands",
      "count": 4,
      "pct": 3.2,
      "base": 126
    },
    {
      "question": "q2",
      "option": "Failure of an adequate trial of topical steroids and non-steroidal topicals",
      "count": 65,
      "pct": 51.6,
      "base": 126
    },
    {
      "question": "q2",
      "option": "The patient asks for a stronger or more convenient treatment",
      "count": 3,
      "pct": 2.4,
      "base": 126
    },
    {
      "question": "q2",
      "option": "Worry about long-term topical steroid use",
      "count": 0,
      "pct": 0,
      "base": 126
    },
    {
      "question": "q3",
      "option": "1 (very unlikely)",
      "count": 0,
      "pct": 0,
      "base": 127
    },
    {
      "question": "q3",
      "option": "2",
      "count": 0,
      "pct": 0,
      "base": 127
    },
    {
      "question": "q3",
      "option": "3",
      "count": 0,
      "pct": 0,
      "base": 127
    },
    {
      "question": "q3",
      "option": "4",
      "count": 28,
      "pct": 22,
      "base": 127
    },
    {
      "question": "q3",
      "option": "5 (very likely)",
      "count": 99,
      "pct": 78,
      "base": 127
    },
    {
      "question": "q4",
      "option": "1 (very unlikely)",
      "count": 0,
      "pct": 0,
      "base": 127
    },
    {
      "question": "q4",
      "option": "2",
      "count": 0,
      "pct": 0,
      "base": 127
    },
    {
      "question": "q4",
      "option": "3",
      "count": 0,
      "pct": 0,
      "base": 127
    },
    {
      "question": "q4",
      "option": "4",
      "count": 7,
      "pct": 5.5,
      "base": 127
    },
    {
      "question": "q4",
      "option": "5 (very likely)",
      "count": 120,
      "pct": 94.5,
      "base": 127
    },
    {
      "question": "q5",
      "option": "1 (very unlikely)",
      "count": 0,
      "pct": 0,
      "base": 127
    },
    {
      "question": "q5",
      "option": "2",
      "count": 0,
      "pct": 0,
      "base": 127
    },
    {
      "question": "q5",
      "option": "3",
      "count": 0,
      "pct": 0,
      "base": 127
    },
    {
      "question": "q5",
      "option": "4",
      "count": 2,
      "pct": 1.6,
      "base": 127
    },
    {
      "question": "q5",
      "option": "5 (very likely)",
      "count": 125,
      "pct": 98.4,
      "base": 127
    },
    {
      "question": "q6",
      "option": "The patient is reluctant to take an injection or a daily tablet",
      "count": 30,
      "pct": 23.6,
      "base": 127
    },
    {
      "question": "q6",
      "option": "Insurance requirements or prior authorisation",
      "count": 84,
      "pct": 66.1,
      "base": 127
    },
    {
      "question": "q6",
      "option": "Safety monitoring or side-effect concerns",
      "count": 4,
      "pct": 3.1,
      "base": 127
    },
    {
      "question": "q6",
      "option": "I want to see a longer trial of topicals first",
      "count": 9,
      "pct": 7.1,
      "base": 127
    },
    {
      "question": "q6",
      "option": "The disease does not score as severe enough",
      "count": 0,
      "pct": 0,
      "base": 127
    }
  ],
  "what_this_is": "Predicted responses from Brox clones, each built from a long-form interview with a real person. Tabulation only: question, option, count, percentage, base. Never per-clone rows.",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "downloads": {
    "csv": "https://reports.brox.ai/insights/insurance-not-clinical-doubt-holds-back-the-eczema-step-from-topicals-to-a-systemic.csv",
    "json": "https://reports.brox.ai/insights/insurance-not-clinical-doubt-holds-back-the-eczema-step-from-topicals-to-a-systemic.json",
    "markdown": "https://reports.brox.ai/insights/insurance-not-clinical-doubt-holds-back-the-eczema-step-from-topicals-to-a-systemic.md",
    "html": "https://reports.brox.ai/insights/insurance-not-clinical-doubt-holds-back-the-eczema-step-from-topicals-to-a-systemic"
  }
}
